SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017048
Filing Date
2022-11-09
Accepted
2022-11-09 09:24:48
Documents
68
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20220930x10q.htm   iXBRL 10-Q 2385890
2 EX-10.4 tbph-20220930xex10d4.htm EX-10.4 13877
3 EX-31.1 tbph-20220930xex31d1.htm EX-31.1 13466
4 EX-31.2 tbph-20220930xex31d2.htm EX-31.2 14255
5 EX-32 tbph-20220930xex32.htm EX-32 16325
  Complete submission text file 0001558370-22-017048.txt   8439456

Data Files

Seq Description Document Type Size
6 EX-101.SCH tbph-20220930.xsd EX-101.SCH 59025
7 EX-101.CAL tbph-20220930_cal.xml EX-101.CAL 69145
8 EX-101.DEF tbph-20220930_def.xml EX-101.DEF 265477
9 EX-101.LAB tbph-20220930_lab.xml EX-101.LAB 491439
10 EX-101.PRE tbph-20220930_pre.xml EX-101.PRE 380476
62 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20220930x10q_htm.xml XML 1380234
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 221370926
SIC: 2834 Pharmaceutical Preparations